(2)
Independent, retrospective review of 2016-2019 surgeon data by University of Washington researchers demonstrates that Conformis iTotal knee replacement implants enable expedited surgical time and reduce length of hospital stay.
BILLERICA, Mass., March 17, 2021 (GLOBE NEWSWIRE) Conformis, Inc. (NASDAQ:CFMS) announced today that an independent, retrospective review of hospital data has concluded that Conformis iTotal knee replacement technology is more cost-effective than leading traditional, off-the-shelf implants. Importantly, this study was independently performed with no sponsorship or funding from Conformis.
The new abstract was presented by authors at the Orthopaedic Research Society 2021 Annual Meeting (ORS 2021 Annual Meeting), held in February 2021:
Custom-designed total knee arthroplasty is cost-effective in comparison to a standard implant (https://www.ors.org/Transactions/67/980.pdf), Navin Fernando MD, Ann Chancellor CCRC, Paul Manner MD, University of Washingt